Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BN-Brachyury + ado-trastuzumab emtansine + bintrafusp alfa
- Development stage
- Unknown
- Lead developer
- Bavarian Nordic
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
This combination involves three distinct therapeutic agents: - **BN-Brachyury**: A recombinant vector-based therapeutic cancer vaccine designed to induce an immune response against brachyury, a protein overexpressed in many solid tumors[1][3]. - **Ado-trastuzumab emtansine (T-DM1)**: An antibody-drug conjugate used to treat HER2-positive breast cancer by linking trastuzumab with the cytotoxic agent emtansine[6][9]. - **Bintrafusp alfa**: A bifunctional fusion protein targeting TGF-β and PD-L1, used in treating cancers like non-small cell lung cancer and cervical cancer[7][10].
- Brand names
- Kadcyla
- Other names
- MVA-BN-brachyurytrastuzumab emtansineM7824M-7824M 7824
02
Targets
T (Brachyury transcription factor)CD274 (Programmed cell death protein 1 ligand 1)TGFB (GARP–latent transforming growth factor beta 1 complex)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on BN-Brachyury + ado-trastuzumab emtansine + bintrafusp alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BN-Brachyury + ado-trastuzumab emtansine + bintrafusp alfa.